Foghorn Therapeutics Inc. announced that Chief Financial Officer, Allan Reine will be departing the Company to pursue another opportunity. The company has commenced a formal search for a successor. Dr. Reine?s last day as a full-time employee with Foghorn will be January 16, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.49 USD | +4.97% | +3.58% | -14.88% |
Apr. 16 | Foghorn Therapeutics Names Kristian Humer CFO | MT |
Apr. 16 | Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.88% | 234M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- FHTX Stock
- News Foghorn Therapeutics Inc.
- Foghorn Therapeutics Inc. Announces Resignation of Allan Reine as Chief Financial Officer, Effective January 16, 2024